Wolfe Research upgraded Ionis Pharmaceuticals to Outperform from Peer Perform with a $58 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals presents results from Phase 3 Balance study olezarsen
- Ionis Pharmaceuticals management to meet with Piper Sandler
- Ionis Pharmaceuticals to present data from Phase 3 on olezarsen
- Ionis announces results from Phase 2 study of ION224
- Ionis Pharmaceuticals price target raised to $72 from $65 at Oppenheimer